OptiNose — Q1 2021 Earnings Presentation
17 slides from OptiNose's earnings presentation, May 5, 2021
Slide 1: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M ay 5 , 2 0 2 1 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this
Slide 3: Key Takeaways and Q1 2021 Highlights
3 Key Takeaways and Q1 2021 Highlights Q1 2021 Performance Aligned with Company Guidance Largest Number of XHANCE New Prescriptions Since Launch Multiple factors support continued revenue growth in 2021 Topline data from one CS trial expected in Q1 2022 +55% XHANCE Net Revenue Growth Q1 2021/Q1 2020
Slide 4: Emerging Consensus Identifies XHANCE as Unique Step in Care for Nasal Polyps
4 Emerging Consensus Identifies Treatment with XHANCE as Unique Step in Care for Patients with Nasal Polyps Recognition of XHANCE by physician experts as a step in between initial care with standard nasal steroid sprays and before escalation of care with surgery or biologic medicines has increased
Slide 5: XHANCE Launch Update
XHANCE Launch Update optinose —=_—
Slide 6: XHANCE New Prescriptions increased 16% and Total Prescriptions increased 30%
6 XHANCE New Prescriptions increased 16% and Total Prescriptions increased 30% from Q1 2020 to Q1 2021 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intranasal steroid prescriptions based o
Slide 7: XHANCE market share increased from 3.4% to 5.2%
7 XHANCE market share increased from 3.4% to 5.2% from Q1 2020 to Q1 2021 and Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter increased by 44% from Q1 2020 to Q1 2021 (1,285 versus 895) The Market on this slide is defined as the sum of all intranasal steroi
Slide 8: Q1 2021 Financial Update
Q1 2021 Financial Update optinose —=_—
Slide 9: Financial Review – First Quarter 2021
9 Financial Review – First Quarter 2021 Q1 2021 XHANCE Net Revenue Increased 55% Compared to Q1 2021 $7.1 $11.0 Q1 '20 Q1 '21 ($M ) Net Revenue +55% $126 $151 Q1 '20 Q1 '21 Average Net Revenue per TRx (Favorable to guidance of $120 ‐ $140)
Slide 10: Full Year 2021 Financial Guidance
10 Full Year 2021 Financial Guidance XHANCE Net Revenue and Average Net Revenue per Prescription ‒ FY 2021 expected to be at least $80 million ‒ Average net revenue per prescription expected to improve substantially for the remainder of 2021 compared to $151 in Q1 2021 ‒ FY 2021 average net revenu
Slide 11: Pipeline Updates
Pipeline Updates optinose —=_—
Slide 12: XHANCE Chronic Sinusitis Indication (sNDA)
12 XHANCE Chronic Sinusitis Indication (sNDA) In April 2021 we completed a blinded interim analysis (IA) to assess the variance in the symptom co‐primary endpoint in trial ‐3205 – The observed variance in the IA is lower than the variance assumed when sample size/power were estimated during the de
Slide 13: OPN-019 Pilot Study
13 OPN‐019 Pilot Study In March we announced a plan to conduct a randomized, adaptive proof of concept single‐dose study to evaluate change in viral load after OPN‐ 019 in adults with COVID‐19 Assessments will include reduction in viral load by qRT‐PCR and in number of infectious viral particles
Slide 14: Closing Remarks
Closing Remarks optinose —=_—
Slide 15: Key Takeaways and Q1 2021 Highlights
15 Key Takeaways and Q1 2021 Highlights Q1 2021 Performance Aligned with Company Guidance Largest Number of XHANCE New Prescriptions Since Launch Multiple factors support continued revenue growth in 2021 Topline data from one CS trial expected in Q1 2022 +55% XHANCE Net Revenue Growth Q1 2021/Q1 202
Slide 16: Investor Relations – Optinose Investor Contact
16 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Operations 267‐521‐0531 1 ‐ Optinose is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding the Company’s performance made by these an
Slide 17: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M ay 5 , 2 0 2 1